A share price of DiaMedica Therapeutics Inc [DMAC] is currently trading at $9.07, up 3.54%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DMAC shares have gain 13.66% over the last week, with a monthly amount glided 53.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 07, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $7 on the stock. Oppenheimer upgraded its rating to an Outperform but $7 remained the price target by the analyst firm on June 22, 2023. Oppenheimer started tracking with an Outperform rating for this stock on April 09, 2021, and assigned it a price target of $27. In a note dated February 17, 2021, ROTH Capital initiated a Buy rating and provided a target price of $38 on this stock.
DiaMedica Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.19 and $9.23. Currently, Wall Street analysts expect the stock to reach $8.33 within the next 12 months. DiaMedica Therapeutics Inc [NASDAQ: DMAC] shares were valued at $9.07 at the most recent close of the market. An investor can expect a potential drop of -8.16% based on the average DMAC price forecast.
Analyzing the DMAC fundamentals
Gross Profit Margin for this corporation currently stands at 0.0% with Operating Profit Margin at -2.28%, Pretax Profit Margin comes in at -2.14%, and Net Profit Margin reading is -2.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.94, Equity is -0.79 and Total Capital is -1.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.79 points at the first support level, and at 8.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.35, and for the 2nd resistance point, it is at 9.63.
Ratios To Look Out For
To put it in perspective, the Current Ratio for DiaMedica Therapeutics Inc [NASDAQ:DMAC] is 10.67. Further, the Quick Ratio stands at 10.67, while the Cash Ratio is 1.0.
Transactions by insiders
Recent insider trading involved STAHLBERG JAN, 10% Owner, that happened on Nov 19 ’25 when 0.24 million shares were purchased. 10% Owner, STAHLBERG JAN completed a deal on Nov 21 ’25 to buy 0.21 million shares. Meanwhile, 10% Owner STAHLBERG JAN bought 0.18 million shares on Nov 18 ’25.
